Navigation Links
Cell Therapeutics and Spectrum Pharmaceuticals Close Transaction Forming Joint Venture to Market Zevalin in the US
Date:12/16/2008

SEATTLE, Dec. 16 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.(CTI) (Nasdaq and MTA: CTIC) announced today they have closed the transaction with Spectrum Pharmaceuticals, Inc. to form a 50/50 owned joint venture, RIT Oncology LLC (LLC), to commercialize and develop Zevalin(R) ([90Y]-ibritumomab tiuxetan) in the United States. In connection with the closing, Cell Therapeutics received an initial payment of $7.5 million and will receive an additional $7.5 million in early January. The Company may earn an additional $15 million in product sales milestone payments upon achievement of certain revenue targets.

"RIT Oncology is the first business venture focused on the advancement of radioimmunotherapy (RIT) in the treatment of lymphoma which provides significant resources to help accomplish that mission," said James A. Bianco, M.D., CEO of Cell Therapeutics, Inc. "RIT like Zevalin has been underutilized since its introduction in 2002. With the potential for a first-line indication for consolidation of remission in patients with follicular non-Hodgkin's lymphoma, we will be uniquely positioned to maximize physician and patient access with this potentially valuable treatment option."

Zevalin, a radioimmunotherapeutic, has been exclusively marketed by CTI in the United States since December, 2007 and will now be marketed jointly by CTI and Spectrum through the LLC for the treatment of patients with relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL), including patients who have rituximab-refractory follicular NHL. The U.S. Food and Drug Administration (FDA) has accepted for filing and review, and has granted priority review status for, a supplemental Biologics License Application (sBLA) filed by CTI for use of Zevalin as consolidation therapy for patients with follicular B-cell non-Hodgkin's lymphoma who achieve a response to first-line therapy. A Prescription Drug User Fee Act (
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Pain Therapeutics Receives Complete Response Letter From FDA for REMOXY(R)
2. Prime Therapeutics Announces Blue Cross and Blue Shield of Montana as a Pharmacy Benefit Services Client
3. Agile Therapeutics Abstracts on Lead Product, AG200-15 Accepted by ACOG
4. Cell Therapeutics, Inc. to Offer to Repurchase up to $124 Million of Its Notes
5. Horizon Therapeutics announces 2 pivotal HZT-501 Phase 3 trials meet primary endpoints
6. Transition Therapeutics Announces Dates for Upcoming Corporate Events
7. Taligen Therapeutics Advances Corporate Growth Plan with Appointment of Jeffrey T. Walsh as Chief Business Officer
8. Precision Therapeutics Secures $43 Million in Venture Capital Funding
9. Nile Therapeutics, Inc. Reports 2008 Third Quarter Financial Results
10. Hyperion Therapeutics Completes Phase 2 Data Analysis and Schedules End of Phase 2 Meeting With FDA for HPN-100 in the Chronic Treatment of Urea Cycle Disorders
11. Transition Therapeutics Announces First Quarter Fiscal 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... West Palm Beach, Florida (PRWEB) September 30, 2014 ... of Florida make the treatment of gum disease ... traditional treatments of the past. , “If you’ve ever felt ... into ice cream or sip a cold beverage, it’s possible ... Herbert Salisbury , who is a general dentist in ...
(Date:9/30/2014)... (HealthDay News) -- Medicare should cover low-dose computed tomography ... the disease, a coalition of more than 60 patient ... the Lung Cancer Alliance, the Society of Thoracic Surgeons, ... and the American Society of Clinical Oncology, made its ... Centers for Medicare & Medicaid Services (CMS). Such ...
(Date:9/30/2014)... made progress in reducing the stigma associated with seeking ... stress disorder, but more improvement is still needed, according ... of both the Defense Department and the Veterans Health ... still do not seek needed care for mental ... to promote treatment as a way to reduce stigma, ...
(Date:9/30/2014)... a gene mutation that causes a rare premature aging ... block the rapid, unstoppable cell division that makes cancer ... Michigan and the U-M Health System recently discovered a ... in which precious hematopoietic stem cells can,t regenerate and ... are prone to cancer and bone marrow failure. ...
(Date:9/30/2014)... FDA-approved injectable dermal fillers (i.e. hyaluronic ... in several procedures that are performed to restore ... primarily used for wrinkle treatment of the skin, ... are being used as popular treatments in nonsurgical ... the hands. (1) (2) Dr. Cynthia Elliott of ...
Breaking Medicine News(10 mins):Health News:Florida Dentist Battles Gum Disease With Latest Techniques 2Health News:Florida Dentist Battles Gum Disease With Latest Techniques 3Health News:Groups Call for Medicare Coverage of Lung Cancer Screening 2Health News:US military making progress reducing stigma tied to seeking help for mental illness 2Health News:US military making progress reducing stigma tied to seeking help for mental illness 3Health News:Disease decoded: Gene mutation may lead to development of new cancer drugs 2Health News:Nonsurgical Cosmetic How-To: Skinspirations Details Proper Use of FDA-Approved Injectable Fillers for Hand Rejuvenation Procedures 2Health News:Nonsurgical Cosmetic How-To: Skinspirations Details Proper Use of FDA-Approved Injectable Fillers for Hand Rejuvenation Procedures 3Health News:Nonsurgical Cosmetic How-To: Skinspirations Details Proper Use of FDA-Approved Injectable Fillers for Hand Rejuvenation Procedures 4
... Hopkins Kimmel Cancer Center researchers say preliminary studies show ... able to reduce or eliminate the last remaining cancer ... the drug Imatinib mesylate (Gleevec). Gleevec, one of ... CML patients, destroys most leukemic cells in the body, ...
... new study, scientists have searched for mutations in the gene regions ... samples from a single tumour type to be sequenced to date. ... type of kidney cancer, with 102,000 deaths worldwide each year. It ... its nature is remarkably consistent and the majority of cases ...
... arthritis (RA) patients are partially protected by the influenza ... determined that while the flu vaccine is safe, it ... months following rituximab treatment. Previous influenza vaccination in ... some defense to influenza strains. RA activity was ...
... /CNW/ - A recent evaluation by the Centre for Addiction ... alcohol use can be effective in changing drinking behaviours and ... first evaluation of its kind, the study published in ... online screener www.CheckYourDrinking.net, reduced their alcohol consumption by 30% - ...
... of mental health professionals, emergency response experts, and researchers ... results of a study that shows serious emotional disturbances ... Category 3 storm ravaged the Gulf Coast in August ... of the Journal of the American Academy of ...
... the US population becomes increasingly obese while smoking rates continue ... contributor to the burden of disease and shortening of healthy ... the February 2010 issue of the American Journal of ... College of New York calculate that the Quality-Adjusted Life Years ...
Cached Medicine News:Health News:Johns Hopkins researchers say vaccine appears to 'mop up' leukemia cells Gleevec leaves behind 2Health News:Unraveling kidney cancer 2Health News:Unraveling kidney cancer 3Health News:Efficacy of flu vaccine drastically reduced for RA patients treated with rituximab 2Health News:Technology new gateway into treatment for problem alcohol users: Study 2Health News:Obesity now poses as great a threat to quality of life as smoking 2
(Date:9/30/2014)... , Sept. 30, 2014 Passport Health, one ... , has launched FluFree.com, a website designed to ... For 20 years, Passport Health has provided ... flu. The launch of FluFree.com is designed to address ... the number of people who actually chose to get ...
(Date:9/30/2014)... September 2014 ... Acutus Medical, Inc. ... 3D-Herzkammer-Bildgebungs- und Dipoldichte-Mappingsystem in Echtzeit zur ... komplexen Herzrhythmusstörungen einschließlich Vorhofflimmern führen bzw. ... zusätzlichen Finanzierung über 26,2 Mio. USD ...
(Date:9/30/2014)... , Sept. 30, 2014  Arena Solutions, the ... today announced its Fall 2014 release, which includes ... and Arena DataExtract – and significant ... available products are focused specifically on speeding time ... aggregation of a complete history of tribal knowledge ...
Breaking Medicine Technology:Passport Health Launches FluFree.com - Aims To Improve Flu Vaccination Rates and Fulfill Growing Public Health Priority 2Passport Health Launches FluFree.com - Aims To Improve Flu Vaccination Rates and Fulfill Growing Public Health Priority 3Acutus Medical, Inc. schließt zusätzliche Finanzierungsrunde Serie B über 26,2 Mio. USD ab, um Portfolio-Erweiterung zu finanzieren 2Acutus Medical, Inc. schließt zusätzliche Finanzierungsrunde Serie B über 26,2 Mio. USD ab, um Portfolio-Erweiterung zu finanzieren 3Arena Unveils Unique PLM Collaboration Platform And New Data Extraction Tool 2Arena Unveils Unique PLM Collaboration Platform And New Data Extraction Tool 3Arena Unveils Unique PLM Collaboration Platform And New Data Extraction Tool 4
... oxygen flowmeters., ,Options: , ... S to model number. Example: ... add suffix C to model ... Double Flowmeters with Power Take-Off, ...
... flowmeters., ,Options: , For ... to model number. Example: FMC107S. ... suffix C to model number. ... Flowmeters with Power Take-Off, add ...
... Slim Line Flowmeters with brass and ... security chain, add suffix S to ... Canadian Color-Code, add suffix C to ... Double Flowmeters with Power Take-Off, add ...
... Flowmeters with brass and aluminum body., ... add suffix S to model number. ... add suffix C to model number. ... with Power Take-Off, add PT to ...
Medicine Products: